Cyclacel gives seliciclib update

Cyclacel (NASDAQ:CYCC) said seliciclib would "probably not" demonstrate an improvement in progression-free survival, the primary endpoint, in the Phase IIb APPRAISE trial to treat non-small cell lung ...